Syngene reports FY26 revenue of Rs 3,739 Cr, up 3%; Q4 revenue at Rs 1,037 Cr

Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities

OneSource Pharma, Dr Reddy’s secure Health Canada nod for generic Semaglutide

Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility

Aurigene bets big on CRDMO expansion with $100 million outlay

Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities

Cipla wins USFDA nod for first generic of Ventolin HFA strengthening respiratory push

The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA

Cipla’s generic Ventolin HFA secures USFDA approval

Approval for Albuterol Sulfate inhalation aerosol enables Cipla Limited to enter the $1.5 billion U.S. albuterol market

Orbicular's partner secures tentative U.S. ANDA approval for a generic version of Ozempic

OneSource is the contract development and manufacturing organization (CDMO) partner for this product

FDA pushes forward on gene-editing therapies with new safety roadmap

Genome editing holds extraordinary promise for treating previously incurable genetic diseases

Precision BioSciences expands Hepatitis B gene editing trial into France and Romania

The Clinical Trial Application (CTA) approval clears the way for the company to launch trial locations in France and Romania

Galderma rolls out next-generation regenerating skin nectar

Aurigene, Alveus advance obesity pipeline with ALV-200 candidate nomination

The collaboration combines Alveus’ expertise in metabolic biology and therapeutic strategy with Aurigene’s integrated discovery capabilities